TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Investing.com - Morgan Stanley initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with an Overweight rating and a $70.00 price target, highlighting the company’s protein degradation and ...

Kymera Therapeutics announces $250.8 million public offering of common stock and pre-funded warrants to advance its biopharmaceutical programs.

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

The latest international Kymera Therapeutics Inc news and views from Reuters - one of the world's largest news agencies ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the ...